6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of July, 2023

(Commission File No. 001-41157)

BIONOMICS LIMITED

(Translation of registrant’s name into English)

200 Greenhill Road

Eastwood SA 5063

Tel: +618 8150 7400

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):

Yes ☐ No ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):

Yes ☐ No ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

The Company today requested an immediate halt to the trading of the Company’s securities quotedon the Australian Securities Exchange (ASX), in accordance with the Listing Rules of ASX. The document is furnished herewith as Exhibit 99.1 to this report on Form 6-K.

1

EXHIBIT INDEX

Exhibit	Description
99.1	Bionomic halts trading of its securities quoted on the ASX

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

Bionomics Limited
(Registrant)
By:	/s/ Alan Fisher
Name:	Alan Fisher
Title:	Chairman

Date: July 24, 2023

1

EX-99.1

Exhibit 99.1

 

24 July 2023

Lisa Banh
Senior Advisor, Listings Compliance

ASX Compliance Pty Limited
20 Bridge Street, Sydney, NSW 2000

By email only

Dear Lisa,

REQUEST FOR TRADING HALT

Bionomics Limited (ASX:BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company, requests an immediate halt to the trading of the Company’s securities quoted on the Australian Securities Exchange (ASX) in accordance with the ASX Listing Rule 17.1.

In accordance with ASX Listing Rule 17.1, the Company provides the following information in relation to the request:

1. The trading halt is requested pending an announcement by Bionomics in relation to an application to be removed from the Official List of the ASX (Announcement).

2. The Company requests that the trading halt remains in place until the earlier of commencement of normal trading on 25 July 2023, or when it makes the Announcement.

3. The Company expects to make the Announcement to ASX before the commencement of normal trading on 25 July 2023.

4. The Company is not aware of any reason why the trading halt should not be granted or of any further information necessary to inform the market about the trading halt.

If you have any further questions, please do not hesitate to contact me.

Yours Sincerely,

Suzanne Irwin

Company Secretary

CoSec@bionomics.com.au

Bionomics Limited | 200 Greenhill Road, Eastwood, South Australia, +61 8 8150 7400, ABN: 53 075 582 740